Pomanda estimates the enterprise value of EPILEPSY RESEARCH INSTITUTE UK at £4.4m based on a Turnover of £3.6m and 1.23x industry multiple (adjusted for size and gross margin).
epilepsy research institute ukEstimated Valuation
£4.4m
Pomanda estimates the enterprise value of EPILEPSY RESEARCH INSTITUTE UK at £4.4m based on an EBITDA of £892.5k and a 4.9x industry multiple (adjusted for size and gross margin).
epilepsy research institute ukEstimated Valuation
£6.7m
Pomanda estimates the enterprise value of EPILEPSY RESEARCH INSTITUTE UK at £6.7m based on Net Assets of £4.2m and 1.59x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Epilepsy Research Institute UkOverview
Epilepsy Research Institute Uk is a live company located in london, WC1R 4SG with a Companies House number of 04873718. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in August 2003, it's largest shareholder is
unknown.
Epilepsy Research Institute Uk is a mature,
small sized company, Pomanda has estimated its turnover at
£3.6m with
rapid
growth in recent years.
Pomanda's financial health check has awarded Epilepsy Research Institute Uk a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 2 areas for improvement. Company Health Check FAQs
Health Rating5out of 5
5 Strong
3 Regular
2 Weak
Size
annual sales of £3.6m, make it in line with the average company (£3.7m)
£3.6m - Epilepsy Research Institute Uk
£3.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 43%, show it is growing at a faster rate (11.9%)
43% - Epilepsy Research Institute Uk
11.9% - Industry AVG
Production
with a gross margin of 53.7%, this company has a comparable cost of product (53.7%)
53.7% - Epilepsy Research Institute Uk
53.7% - Industry AVG
Profitability
an operating margin of 24.8% make it more profitable than the average company (-5.6%)
24.8% - Epilepsy Research Institute Uk
-5.6% - Industry AVG
Employees
with 10 employees, this is below the industry average (46)
10 - Epilepsy Research Institute Uk
46 - Industry AVG
Pay Structure
on an average salary of £60.2k, the company has a lower pay structure (£77.1k)
£60.2k - Epilepsy Research Institute Uk
£77.1k - Industry AVG
Efficiency
resulting in sales per employee of £359.5k, this is more efficient (£124.5k)
£359.5k - Epilepsy Research Institute Uk
£124.5k - Industry AVG
Debtor Days
it gets paid by customers after 0 days, this is earlier than average (53 days)
0 days - Epilepsy Research Institute Uk
53 days - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Epilepsy Research Institute Uk
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Epilepsy Research Institute Uk
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 33 weeks, this is average cash available to meet short term requirements (33 weeks)
33 weeks - Epilepsy Research Institute Uk
33 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 60.6%, this is a higher level of debt than the average (51.3%)
60.6% - Epilepsy Research Institute Uk
51.3% - Industry AVG
EPILEPSY RESEARCH INSTITUTE UK financials
EXPORT
Epilepsy Research Institute Uk's latest turnover from March 2024 is £3.6 million and the company has net assets of £4.2 million. According to their latest financial statements, Epilepsy Research Institute Uk has 10 employees and maintains cash reserves of £2.2 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Turnover
3,595,109
3,605,370
2,853,423
1,226,279
2,255,094
2,652,089
2,227,790
1,402,998
1,236,209
1,378,430
1,153,133
1,141,339
1,831,979
1,160,189
1,128,853
Other Income Or Grants
Cost Of Sales
1,663,549
1,675,491
1,466,384
599,631
1,116,945
1,294,585
1,061,126
718,106
669,135
739,504
639,005
624,836
1,007,218
568,306
507,157
Gross Profit
1,931,560
1,929,879
1,387,039
626,648
1,138,149
1,357,504
1,166,664
684,892
567,074
638,926
514,129
516,503
824,761
591,883
621,696
Admin Expenses
1,039,030
1,225,506
496,534
1,149,110
996,495
114,512
482,821
614,033
607,146
659,775
507,706
494,914
577,469
552,371
510,858
Operating Profit
892,530
704,373
890,505
-522,462
141,654
1,242,992
683,843
70,859
-40,072
-20,849
6,423
21,589
247,292
39,512
110,838
Interest Payable
Interest Receivable
Pre-Tax Profit
782,688
683,854
740,827
-519,281
117,306
1,024,891
563,558
61,746
-25,489
-6,465
16,050
26,320
190,939
35,648
83,304
Tax
Profit After Tax
782,688
683,854
740,827
-519,281
117,306
1,024,891
563,558
61,746
-25,489
-6,465
16,050
26,320
190,939
35,648
83,304
Dividends Paid
Retained Profit
782,688
683,854
740,827
-519,281
117,306
1,024,891
563,558
61,746
-25,489
-6,465
16,050
26,320
190,939
35,648
83,304
Employee Costs
601,685
489,136
393,619
384,923
325,317
249,996
290,749
268,121
230,716
209,610
186,903
166,884
154,546
144,172
141,643
Number Of Employees
10
10
8
8
8
5
6
5
5
4
5
4
4
4
4
EBITDA*
892,530
704,373
890,505
-522,462
141,654
1,242,992
683,843
70,859
-40,072
-20,849
6,423
21,589
247,292
39,512
110,838
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Tangible Assets
Intangible Assets
Investments & Other
7,552,532
3,740,842
3,897,165
2,311,606
2,016,232
1,056,210
519,430
514,081
Debtors (Due After 1 year)
47,133
Total Fixed Assets
7,552,532
3,740,842
3,897,165
2,311,606
2,016,232
1,056,210
519,430
514,081
47,133
Stock & work in progress
Trade Debtors
4,970
7,486
6,633
20,831
11,491
23,868
23,861
9,721
Group Debtors
Misc Debtors
841,121
1,860,583
733,442
587,801
1,120,503
960,832
767,238
457,311
427,975
445,113
392,724
382,592
315,798
234,361
Cash
2,197,361
3,557,081
3,026,035
3,399,537
2,962,503
3,373,391
2,574,716
2,188,527
2,870,038
2,963,289
2,790,240
2,978,080
2,238,779
2,054,774
1,944,832
misc current assets
960,885
total current assets
3,043,452
5,425,150
3,766,110
4,008,169
4,094,497
4,358,091
3,365,815
2,645,838
3,298,013
3,408,402
3,182,964
3,360,672
3,209,385
2,370,572
2,179,193
total assets
10,595,984
9,165,992
7,663,275
6,319,775
6,110,729
5,414,301
3,885,245
3,159,919
3,298,013
3,455,535
3,182,964
3,360,672
3,209,385
2,370,572
2,179,193
Bank overdraft
Bank loan
Trade Creditors
180
1,644,784
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
3,417,158
2,926,568
2,007,029
1,956,691
1,553,440
1,777,291
1,260,610
1,329,763
1,348,675
1,758,126
1,522,114
1,530,091
1,161,678
979,492
total current liabilities
3,417,158
2,926,568
2,007,029
1,956,691
1,553,440
1,777,291
1,260,790
1,329,763
1,348,675
1,758,126
1,522,114
1,530,091
1,644,784
1,161,678
979,492
loans
hp & lease commitments
Accruals and Deferred Income
13,820
other liabilities
3,000,554
2,843,840
2,944,516
2,392,181
2,067,105
1,264,132
1,276,468
1,035,532
1,228,947
951,529
908,505
1,094,286
840,806
689,858
716,313
provisions
total long term liabilities
3,000,554
2,843,840
2,944,516
2,392,181
2,067,105
1,264,132
1,276,468
1,035,532
1,228,947
951,529
908,505
1,094,286
854,626
689,858
716,313
total liabilities
6,417,712
5,770,408
4,951,545
4,348,872
3,620,545
3,041,423
2,537,258
2,365,295
2,577,622
2,709,655
2,430,619
2,624,377
2,499,410
1,851,536
1,695,805
net assets
4,178,272
3,395,584
2,711,730
1,970,903
2,490,184
2,372,878
1,347,987
794,624
720,391
745,880
752,345
736,295
709,975
519,036
483,388
total shareholders funds
4,178,272
3,395,584
2,711,730
1,970,903
2,490,184
2,372,878
1,347,987
794,624
720,391
745,880
752,345
736,295
709,975
519,036
483,388
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Operating Activities
Operating Profit
892,530
704,373
890,505
-522,462
141,654
1,242,992
683,843
70,859
-40,072
-20,849
6,423
21,589
247,292
39,512
110,838
Depreciation
Amortisation
Tax
Stock
Debtors
-1,021,978
1,127,994
131,443
-523,362
147,294
193,601
333,788
29,336
-64,271
99,522
10,132
372,871
-306,077
81,437
234,361
Creditors
-180
180
-1,644,784
1,644,784
Accruals and Deferred Income
490,590
919,539
50,338
403,251
-223,851
516,681
-69,153
-18,912
-409,451
236,012
-7,977
1,516,271
-1,147,858
182,186
979,492
Deferred Taxes & Provisions
Cash flow from operations
2,405,098
495,918
809,400
404,151
-229,491
1,565,892
281,082
22,611
-385,252
115,641
-11,686
-479,795
1,050,295
140,261
855,969
Investing Activities
capital expenditure
-15,544
-501,594
Change in Investments
3,811,690
-156,323
1,585,559
295,374
960,022
536,780
5,349
514,081
cash flow from investments
-3,811,690
156,323
-1,585,559
-295,374
-960,022
-536,780
-20,893
-1,015,675
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
156,714
-100,676
552,335
325,076
802,973
-12,336
240,936
-193,415
277,418
43,024
-185,781
253,480
150,948
-26,455
716,313
share issue
-10,195
12,487
400,084
interest
cash flow from financing
156,714
-100,676
552,335
325,076
802,973
-12,336
230,741
-180,928
277,418
43,024
-185,781
253,480
150,948
-26,455
1,116,397
cash and cash equivalents
cash
-1,359,720
531,046
-373,502
437,034
-410,888
798,675
386,189
-681,511
-93,251
173,049
-187,840
739,301
184,005
109,942
1,944,832
overdraft
change in cash
-1,359,720
531,046
-373,502
437,034
-410,888
798,675
386,189
-681,511
-93,251
173,049
-187,840
739,301
184,005
109,942
1,944,832
epilepsy research institute uk Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for epilepsy research institute uk. Get real-time insights into epilepsy research institute uk's credit score, group structure and payment trends.
Epilepsy Research Institute Uk Competitor Analysis
Perform a competitor analysis for epilepsy research institute uk by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in WC1R area or any other competitors across 12 key performance metrics.
epilepsy research institute uk Ownership
EPILEPSY RESEARCH INSTITUTE UK group structure
Epilepsy Research Institute Uk has no subsidiary companies.
Ultimate parent company
EPILEPSY RESEARCH INSTITUTE UK
04873718
EPILEPSY RESEARCH INSTITUTE UK Shareholders
The sole shareholder of Epilepsy Research Institute Uk is -.
-
-
epilepsy research institute uk directors
Epilepsy Research Institute Uk currently has 16 directors.
The longest serving directors include
Mr Barrie Akin (Aug 2003) and
Professor Matthew Walker (Mar 2011).
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
72110 - Research and experimental development on biotechnology
incorporation date
August 2003
age
22
incorporated
UK
ultimate parent company
None
accounts
Full Accounts
last accounts submitted
March 2024
previous names
epilepsy research uk (June 2023)
epilepsy research foundation (March 2007)
accountant
-
auditor
KRESTON REEVES LLP
address
churchill house, 35 red lion square, london, WC1R 4SG
Bank
C A F BANK LTD
Legal Advisor
WITHERS LLP
epilepsy research institute uk Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to epilepsy research institute uk. Currently there are 0 open charges and 3 have been satisfied in the past.
epilepsy research institute uk Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for EPILEPSY RESEARCH INSTITUTE UK. This can take several minutes, an email will notify you when this has completed.
epilepsy research institute ukCompanies House Filings - See Documents
